<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00182169</url>
  </required_header>
  <id_info>
    <org_study_id>2004h00512</org_study_id>
    <nct_id>NCT00182169</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of Human Recombinant Growth Hormone in Patients With Advanced Heart Failure</brief_title>
  <official_title>Randomized, Placebo Control, Clinical Trial Evaluating the Effect of Human Recombinant Growth Hormone in Patients With Severe Congestive Heart Failure. The Growth Hormone In Heart Failure Trial (GIFT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McMaster University</source>
  <brief_summary>
    <textblock>
      Prospective randomized, placebo controlled, clinical trial to evaluate the effect of human&#xD;
      growth hormone supplementation compared with placebo to patients with severe heart failure&#xD;
      for a duration of 6 months on exercise capacity, heart function and quality of life&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1997</start_date>
  <completion_date>June 2005</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>6-minute walk test distance (functional capacity)measured at baseline, 3 months, and 6 months from the start of the study. Also measured at 3 months following discontinuation of therapy</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac Function measured with radionuclide angiography and echocardiography</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity measured during treadmill testing (duration of exercise)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured with Minnesota Living with Heart Failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurohormones</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>baseline, 3 months, and 6 months from the start of the study. Also measured at 3 months following discontinuation of therapy</measure>
  </secondary_outcome>
  <enrollment>80</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human recombinant growth hormone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Individuals with a diagnosis of CHF, NYHA functional class III or IV symptoms, an EF of &lt;&#xD;
        35 % estimated on radionuclide angiography (RNA) or 2D echo within the last 6 months, and a&#xD;
        6 minute walk distance of less than 400 meters. Patients must be stabilized on &quot;CHF&quot;&#xD;
        therapy at the time of randomization.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Exercise limited by claudication, angina, neurological, pulmonary (FEV1 &lt; 50%; FVC &lt;&#xD;
             50%), or musculoskeletal disease.&#xD;
&#xD;
          2. Active known malignancy; remission of &lt; 5 years from the diagnosis of malignancy;&#xD;
             patients with recurrence of malignancy are to be withdrawn from the study.&#xD;
&#xD;
          3. Current diabetes with known retinopathy or patients with poorly controlled diabetes&#xD;
             (ie. fasting glucose more than 13 mmol/l) or Type I diabetes mellitus.&#xD;
&#xD;
          4. Any other non-cardiac condition that substantially decreases survival.&#xD;
&#xD;
          5. Significant valvular stenosis or hypertrophic cardiomyopathy.&#xD;
&#xD;
          6. Unable to comply with GH injection.&#xD;
&#xD;
          7. Pregnancy or women of child bearing age not using adequate contraceptive means.&#xD;
&#xD;
          8. Unstable angina, acute myocardial infarct, cardiac surgery, or PTCA within 3 months.&#xD;
&#xD;
          9. Cor pulmonale.&#xD;
&#xD;
         10. Acute myocarditis.&#xD;
&#xD;
         11. Known need for cardiac surgery (e.g., valvular intervention, or CABG, or PTCA) within&#xD;
             the next 6 months.&#xD;
&#xD;
         12. Clinical hypothyroidism or hyperthyroidism with biochemical corroboration (TSH &gt; 7 or&#xD;
             &lt; 0.2) at screening.&#xD;
&#xD;
         13. Patients in need of urgent heart transplant within the next 6 months (patients on&#xD;
             transplant list remain eligible).&#xD;
&#xD;
         14. Sustained ventricular tachycardia (lasting &gt; 30 seconds) on screening Holter.&#xD;
&#xD;
         15. Significant liver disease (INR&gt;1.4 off anticoagulant therapy; or AST, or ALT, or GGT,&#xD;
             or alkaline phosphatase &gt; 3X upper limit of normal; or bilirubin &gt; 2X the upper limit&#xD;
             of normal) at baseline.&#xD;
&#xD;
         16. Failure to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Demers, MD, MSc, FRCPC</last_name>
    <role>Study Director</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2003</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>September 12, 2005</last_update_submitted>
  <last_update_submitted_qc>September 12, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2005</last_update_posted>
  <keyword>Severe heart failure</keyword>
  <keyword>Growth hormone</keyword>
  <keyword>exercise capacity</keyword>
  <keyword>quality of life</keyword>
  <keyword>cardiac function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

